Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 avr. 2021 16h15 HE
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, April 01, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and...
Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress
30 mars 2021 16h26 HE
|
Chinook Therapeutics, Inc.
Key presentations for BION-1301 at the ISN World Congress of Nephrology 2021 in April include Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and Part 2 of the ongoing phase 1 study of...
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
16 mars 2021 08h15 HE
|
Chinook Therapeutics, Inc.
Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021 VANCOUVER, British Columbia and SEATTLE, March 16, 2021 (GLOBE...
Chinook Therapeutics to Present at Upcoming Investor Conferences
02 mars 2021 16h15 HE
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and...
Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases
01 mars 2021 08h15 HE
|
Chinook Therapeutics, Inc.
Collaboration will Leverage Access to the NURTuRE Patient Biobank and Evotec’s PanHunter Multi-Omics Platform to Characterize Molecular Drivers, Identify and Validate Novel Targets and Drive Patient...
Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit
23 févr. 2021 08h15 HE
|
Chinook Therapeutics, Inc.
Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials ...
Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
17 févr. 2021 16h15 HE
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and...
Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria
02 févr. 2021 08h15 HE
|
Chinook Therapeutics, Inc.
CHK-336 On Track for Phase 1 Clinical Trial Initiation in the Second Half of 2021 VANCOUVER, British Columbia and SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:...
Chinook Therapeutics to Present at Upcoming Investor Conferences
04 janv. 2021 08h15 HE
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and...
Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities
08 déc. 2020 08h15 HE
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development...